Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Astellas Aims at Overseas Vaccines Market
October 11, 2010
- Revolade Recommended for Approval
October 11, 2010
- ASKA, Senju Create Ceolia Pharma
October 11, 2010
- Fingolimod Approved in the US: Novartis
October 11, 2010
- CMIC Licenses Ecallantide for HAE from Dyax
October 11, 2010
- Gov't, Industry to Discuss How to Ensure Stable Supply of Molybdenum
October 11, 2010
- Panelists Call For Support of Ventures: BioJapan 2010
October 11, 2010
- L-FABP Testing Agent Approved: CMIC
October 11, 2010
- Mediceo to Build Cost-Conscious Company: President Watanabe
October 11, 2010
- Roche to Seek More Alliance Opportunities to Develop Innovative Drugs
October 11, 2010
- New Premium Should Not Affect Price Negotiations: Yonbyokyo
October 11, 2010
- Eisai Ties Up with Anaeropharma to Develop Anticancer Agents
October 11, 2010
- MSD Aims to Become Top-3 Company in Japan
October 11, 2010
- Nitto Denko to Develop siRNA Drugs in the US
October 11, 2010
- Eisai Licenses Ravuconazole Prodrug to Brain Factory
October 11, 2010
- Japan, South Korea, China to Jointly Study Ethnic Differences
October 11, 2010
- Nippon Shinyaku Licenses Prulifloxacin to Algorithm
October 11, 2010
- Takeda to Set Up Subsidiary in India
October 11, 2010
- JPMA President Hasegawa Calls For Enhancement of R&D Tax Break System
October 11, 2010
- DSP Obtains Option Right for SB623 from SanBio
October 11, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…